Fundraising Fox
Code Biotherapeutics
Hatfield, US · Founded 2020 · 24 employees on LinkedIn · 8 known investors
Find your way into Code Biotherapeutics
Sign up to see every warm intro you have to Code Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Code Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver. The platform is designed for re-dosing, delivery of large gene constructs approaching 10kb, and modular manufacturing for genetic medicine development.
Founders & leadership
Board
Investors · 8
How we know: a partner's Signal profile · funding news · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · the VCSheet dataset · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: a partner's Signal profile · funding news · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$47.5M disclosed across 2 rounds · 2021–2022
▶$37.5MraisedJun 2022 · 10 investors · Other Health CareRule 506(b)
- Joseph TruittDirector
- Victor StoneDirector
- Brian McVeighExecutive Officer, Director
- Edward MathersDirector
- Kathy RouanDirector
- Robert C GettsExecutive Officer
- Robert LinDirector
- Dmitry KuzminDirector
- Russ FeinExecutive Officer, Director
- Lauren KaskielExecutive Officer
- Erin BrubakerExecutive Officer
- Offering amount
- $75M
- Amount sold
- $37.5M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$10MraisedApr 2021 · 6 investors · Other Health CareRule 506(b)
- Dmitry KuzminDirector
- Victor StoneDirector
- Lauren KaskielExecutive Officer
- Robert C. GettsExecutive Officer
- Joseph TruittDirector
- Edward MathersDirector
- Brian McVeighExecutive Officer, Director
- Kathy RouanDirector
- Robert LinDirector
- Russ FeinDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Code Biotherapeutics do?
- Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver. The platform is designed for re-dosing, delivery of large gene constructs approaching 10kb, and modular manufacturing for genetic medicine development.
- Who are Code Biotherapeutics's investors?
- Code Biotherapeutics's investors include New Enterprise Associates (NEA), 4BIO Capital, Amgen Ventures, Hatteras Venture Partners, JDRF T1D Fund, Northpond Ventures, Takeda Ventures, UCB Ventures.
- How much funding has Code Biotherapeutics raised?
- Code Biotherapeutics has disclosed $47.5M raised across 2 rounds.
- Where is Code Biotherapeutics headquartered?
- Code Biotherapeutics is headquartered in Hatfield, US.